ClinicalTrials.gov
ClinicalTrials.gov Menu

EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer (EXPERT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02889874
Recruitment Status : Recruiting
First Posted : September 7, 2016
Last Update Posted : October 10, 2018
Sponsor:
Collaborators:
Breast International Group
International Breast Cancer Study Group
Information provided by (Responsible Party):
Breast Cancer Trials, Australia and New Zealand

Brief Summary:
This is a randomised, phase III, non-inferiority trial evaluating radiation therapy versus observation following breast conserving surgery and planned endocrine therapy in patients with stage I breast cancer of luminal A subtype defined using the Prosigna (PAM50) Assay.

Condition or disease Intervention/treatment Phase
Early Stage Breast Carcinoma Radiation: Omission of radiation therapy Not Applicable

Detailed Description:

Radiation therapy (RT) after breast conserving surgery to improve local control and survival is the current standard of care for patients with early breast cancer. However, breast cancer is a heterogeneous disease, and the absolute benefit of RT in individual patients varies substantially. Thus, a pressing priority in contemporary breast cancer management is to tailor RT utilisation to the individual recurrence risks by identifying patients who are unlikely to benefit from RT, thereby avoiding the morbidity and costs of over-treatment.

It is recognised that selected patients with early breast cancer are unlikely to derive benefits from RT after breast conserving surgery. However, randomised trials have not consistently identified patients who may safely omit RT using conventional clinical-pathologic characteristics.

Breast cancer intrinsic subtypes distinguished by gene expression profiling are shown to be associated with distinct clinical outcomes. There is substantial evidence supporting the clinical validity of multigene assays including the PAM50-based Prosigna Assay that identifies intrinsic subtypes and generates a Risk of Recurrence score (ROR) to quantify individual risks of distant relapse. Multigene assays are increasingly integrated into clinical practice to inform chemotherapy decision, highlighting their substantial practice changing potential in personalising the use of RT for early breast cancer.

A recent analysis of archived tumour specimens of 1,308 patients with early breast cancer has shown significant associations between local recurrence risk and the PAM50-defined intrinsic subtypes and ROR score. EXPERT presents a unique opportunity of clinical and public health importance to optimise personalised local therapy for early breast cancer through precise, individualised quantification of local recurrence risk to identify low-risk patients for whom RT after breast conserving surgery may be safely omitted.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1167 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomised Phase III Trial of Adjuvant Radiation Therapy Versus Observation Following Breast Conserving Surgery and Endocrine Therapy in Patients With Molecularly Characterised Luminal A Early Breast Cancer
Actual Study Start Date : August 21, 2017
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
No Intervention: A: Radiation Therapy & endocrine therapy
Patients randomized to Arm A will receive standard radiation therapy and adjuvant endocrine therapy (standard of care).
Experimental: B: No Radiation Therapy (ET only)
Patients randomized to Arm B will not receive radiation therapy (omission of radiation therapy) and receive adjuvant endocrine therapy only.
Radiation: Omission of radiation therapy
Omission of radiation therapy (adjuvant endocrine therapy only).




Primary Outcome Measures :
  1. Local recurrence rate after breast conserving surgery [ Time Frame: 10 years ]
    The time from randomisation to the date of local recurrence (LR) as a site of first recurrence.


Secondary Outcome Measures :
  1. Local-regional recurrence-free interval (LRRFI) [ Time Frame: 10 years ]
    Time from randomisation to the date of local or regional recurrence as a site of first recurrence.

  2. Distant recurrence-free interval (DRFI) [ Time Frame: 10 years ]
    Time from randomisation to the date of distant recurrence, regardless of occurrence of any intervening local or regional recurrence, contralateral breast cancer or second (non-breast) primary invasive cancer.

  3. Disease free survival including DCIS (DFS-DCIS) [ Time Frame: 10 years ]
    Time from randomisation to date of first evidence of local (invasive breast carcinoma or DCIS), regional or distanct recurrence; contralateral breast cancer (invasive breast carcinoma or DCIS); second (non-breast) primary invasive cancer; or death.

  4. Invasive disease free survival (iDFS) [ Time Frame: 10 years ]
    Time from randomisation to date of first evidence of local (invasive breast carcinoma), regional or distanct recurrence; contralateral breast cancer (invasive breast carcinoma); second (non-breast) primary invasive cancer; or death.

  5. Recurrence-free interval [ Time Frame: 10 years ]
    Time from randomisation to the date of local, regional or distant recurrence as a site of first recurrence.

  6. Overall survival (OS) [ Time Frame: 10 years ]
    Time from randomisation to date of death from any cause.

  7. Salvage RT or mastectomy rate [ Time Frame: 10 years ]
    Time from randomisation to the receipt of salvage RT or mastectomy, individually and in combination (one or the other) as a composite endpoint.

  8. Adverse events for patients [ Time Frame: 5 years ]
    Adverse events during treatment (up to 5 years of endocrine therapy) assessed using NCI CTCAE v4.0.

  9. Assessment of the impact of endocrine therapy [ Time Frame: 5 years ]
    FACT-ES measure of endocrine symptoms.


Other Outcome Measures:
  1. Quality of Life: Fear of recurrence [ Time Frame: 5 years ]
    Fear of Cancer Recurrence Inventory

  2. Quality of Life: Convenience of care [ Time Frame: 5 years ]
    Visual Analogue Scales (convenience and impact of treatment)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: for registration in the study:

  1. Female patients aged ≥ 50 years of any menopausal status.
  2. Primary tumour characteristics as assessed by conventional histopathology:

    • Unifocal histologically confirmed invasive breast carcinoma
    • Maximum microscopic size ≤2 cm
    • Grade 1 or 2 histology
    • ER and PR positive in ≥10% of tumour cells in either the biopsy or breast conserving surgical specimen
    • HER2 negative on IHC (score 0 or 1+) or in situ hybridisation (ERBB2-amplification Ratio ERBB2/centromeres <2.0 or mean gene copy number <6). Equivocal IHC score (2+) must be assessed by ISH.
  3. Primary tumour must be resected by breast conserving surgery with microscopically negative margins for invasive carcinoma and any associated ductal carcinoma in situ (no cancer cells adjacent to any inked edge/surface of specimen) or re-excision showing no residual disease.
  4. Histologically confirmed negative nodal status determined by sentinel node biopsy or axillary dissection. Patients with pN0 (i+) disease are eligible for study participation (malignant cells ≤0.2 mm in regional lymph node(s) detected by hematoxylin-eosin (H&E) stain or IHC, including isolated tumour cells).
  5. No evidence of distant metastasis.
  6. Eligible for and willing to have adjuvant endocrine therapy.
  7. ECOG performance status 0-2.
  8. Availability of FFPE tumour block for Prosigna (PAM50) Assay.

For randomization to the study, patients must fulfill all of the following criteria:

1. Primary tumour characteristics as assessed by Prosigna (PAM50) Assay:

  • Luminal A intrinsic subtype
  • ROR score ≤60

Exclusion Criteria:

Any one of the following is regarded as a criterion for exclusion from the study:

  1. Primary tumour characteristics:

    • Presence of multifocal or multicentric invasive carcinoma or ductal carcinoma in situ;
    • Evidence of clinical or pathologic T4 disease (extension to the chest wall, oedema or ulceration of skin, satellite skin nodules, inflammatory carcinoma);
    • The invasive component of the primary tumour is present as micro-invasion only;
    • Grade 3 histology;
    • Presence of lymphovascular invasion
  2. Contra-indication or unwillingness to have adjuvant endocrine therapy.
  3. Planned to receive adjuvant chemotherapy or biologic therapy after breast cancer surgery, i.e. any systemic therapy other than endocrine therapy is not permitted. Any therapy unrelated to cancer is permitted at the discretion of investigators.
  4. Treated with neoadjuvant endocrine therapy, chemotherapy or biologic therapy prior to breast cancer surgery.
  5. Prior breast or thoracic RT for any condition.
  6. Pre-operative breast imaging evidence of disease aside from the primary carcinoma resected by breast conserving surgery.
  7. Concurrent invasive breast carcinoma or ductal carcinoma in situ (synchronous or metachronous).
  8. Prior diagnosis of invasive breast carcinoma or ductal carcinoma in situ in either breast irrespective of disease free interval.
  9. A diagnosis of non-breast malignancy <5 years prior to randomisation with the following exceptions:

    • Patients who are diagnosed with carcinoma in situ of cervix, endometrium or colon; melanoma in situ; and basal or squamous cell carcinoma of the skin at any time prior to randomisation are not excluded from study participation.
    • Patients who are diagnosed with other non-breast malignancy ≥5 years prior to randomisation and without evidence of disease recurrence are not excluded from study participation.
  10. Significant comorbidity precluding definitive RT for breast cancer (e.g. cardiovascular or pulmonary disease, scleroderma, systemic lupus erythematosus).
  11. Life expectancy <10 years.
  12. Documented mutation of BRCA1, BRCA2 or TP53, or at high genetic risk of breast cancer.
  13. Pregnant or lactating patients.
  14. Inability to be registered to the study ≤8 weeks after the last surgical procedure for breast cancer.
  15. Inability to commence RT (if randomised to receive RT) no later than 12 weeks from the last surgical procedure for breast cancer.
  16. Inability to provide written informed consent.
  17. Psychiatric, addictive, or any disorder that precludes compliance with protocol requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02889874


Contacts
Contact: Heath Badger +61 2 4925 5239 expert@bctrials.org.au
Contact: Akiko Fong +61 2 4925 5230 expert@bctrials.org.au

Locations
Australia, Australian Capital Territory
The Canberra Hospital Recruiting
Canberra, Australian Capital Territory, Australia, 2605
Contact: Lisa Sullivan, Dr         
Australia, New South Wales
Macarthur Cancer Therapy Centre Recruiting
Campbelltown, New South Wales, Australia, 2560
Contact: George Papadatos, Dr         
St Vincent's Hospital, Sydney Recruiting
Darlinghurst, New South Wales, Australia, 2010
Contact: Joanne Toohey, Dr         
Genesis Cancer Care Newcastle Recruiting
Gateshead, New South Wales, Australia, 2290
Contact: Peter O'Brien, A/Prof         
Gosford Hospital Not yet recruiting
Gosford, New South Wales, Australia, 2250
Contact: Hester Lieng, Dr         
Principal Investigator: Hester Lieng, Dr         
Liverpool Hospital Recruiting
Liverpool, New South Wales, Australia, 1871
Contact: Miriam Boxer, Dr         
Mater Hospital Sydney Recruiting
North Sydney, New South Wales, Australia, 2060
Contact: Andrew Spillane, Prof         
Port Macquarie Base Hospital Recruiting
Port Macquarie, New South Wales, Australia, 2444
Contact: Carmen Hansen, Dr         
Prince of Wales Hospital Recruiting
Randwick, New South Wales, Australia, 2031
Contact: Boon H Chua, Prof         
Tamworth Rural Referral Hospital Recruiting
Tamworth;, New South Wales, Australia, 2340
Contact: Susan Pendlebury, Dr         
Westmead Hospital Recruiting
Westmead, New South Wales, Australia, 2145
Contact: Verity Ahern, A/Prof         
Wollongong Hospital Recruiting
Wollongong, New South Wales, Australia, 2500
Contact: de Leon Jeremiah, Dr         
Australia, Queensland
Genesis Cancer Care Wesley Recruiting
Auchenflower, Queensland, Australia, 4066
Contact: Marie Burke, Dr         
Princess Alexandra Hospital Recruiting
Woolloongabba, Queensland, Australia, 4102
Contact: Margot Lehman, A/Prof         
Australia, Victoria
Peter MacCallum Cancer Centre - Bendigo Recruiting
Bendigo, Victoria, Australia, 3550
Contact: Solveig Grenfell, Dr         
Peter MacCallum Cancer Centre - Moorabin Recruiting
Bentleigh East, Victoria, Australia, 3165
Contact: Steven David, Dr         
Box Hill Hospital Recruiting
Box Hill, Victoria, Australia, 3128
Contact: Bianca Devitt, Dr         
Icon Cancer Centre Richmond Recruiting
East Melbourne, Victoria, Australia, 3002
Contact: Andrew See, Dr         
St Vincent's Hospital Melbourne Recruiting
Fitzroy, Victoria, Australia, 3065
Contact: Melissa Moore, Dr         
GenesisCare Radiation Oncology Centre Frankston Recruiting
Frankston, Victoria, Australia, 3199
Contact: David Blakey, Dr         
University Hospital Geelong Recruiting
Geelong, Victoria, Australia, 3220
Contact: Michael Francis, Dr         
Austin Hospital Not yet recruiting
Heidelberg, Victoria, Australia, 3084
Contact: Michael Chao, Dr         
Peter MacCallum Cancer Centre Recruiting
Melbourne, Victoria, Australia, 8006
Contact: Prue Francis, A/Prof         
Ringwood Radiation Oncology Centre Recruiting
Ringwood East, Victoria, Australia, 3135
Contact: Michael Chao, Dr         
Australia, Western Australia
Sir Charles Gairdner Hospital Recruiting
Nedlands, Western Australia, Australia, 6009
Contact: Mandy Taylor, Dr         
New Zealand
Christchurch Hospital Recruiting
Christchurch, New Zealand, 8011
Contact: Melissa James, Dr         
Waikato Hospital Recruiting
Hamilton, New Zealand, 3240
Contact: Ian Campbell, A/Prof         
Palmerston North Hospital Recruiting
Palmerston North, New Zealand, 4414
Contact: Claire Hardie, Dr         
Wellington Hospital Recruiting
Wellington, New Zealand, 6021
Contact: Anna Nicholson, Dr         
Sponsors and Collaborators
Breast Cancer Trials, Australia and New Zealand
Breast International Group
International Breast Cancer Study Group
Investigators
Study Director: Phillipa Lee Breast Cancer Trials, Australia and New Zealand
Study Chair: Boon H Chua, Prof Prince of Wales Hospital

Additional Information:
Responsible Party: Breast Cancer Trials, Australia and New Zealand
ClinicalTrials.gov Identifier: NCT02889874     History of Changes
Other Study ID Numbers: ANZ1601/BIG 16-02
2016-003527-33 ( EudraCT Number )
First Posted: September 7, 2016    Key Record Dates
Last Update Posted: October 10, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: to be defined.

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Breast Cancer Trials, Australia and New Zealand:
Radiation therapy
omission
non-inferiority
breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases